We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Incyte Hit With CRL on PD-1 Inhibitor Calling for More Data
Incyte Hit With CRL on PD-1 Inhibitor Calling for More Data
The FDA has slapped Incyte with a Complete Response Letter (CRL) for its biologics license application (BLA) for retifanlimab, the company’s intravenous PD-1 inhibitor for the treatment of certain types of anal cancer, asking for additional data to show the drug’s clinical benefit.
